{
  "prefix": {
    "pe": "https://proofengine.info/proofs/glp-1-drugs-like-ozempic-cause-unavoidable-major-muscle-loss-and-ozempic-face/",
    "prov": "http://www.w3.org/ns/prov#",
    "xsd": "http://www.w3.org/2001/XMLSchema#",
    "schema": "http://schema.org/"
  },
  "entity": {
    "pe:claim": {
      "prov:type": "pe:Claim",
      "prov:label": "GLP-1 drugs like Ozempic cause unavoidable major muscle loss and \"Ozempic face\" even with exercise and high protein intake",
      "prov:value": "GLP-1 drugs like Ozempic cause unavoidable major muscle loss and \"Ozempic face\" even with exercise and high protein intake"
    },
    "pe:evidence-B1": {
      "prov:type": "pe:EmpiricalEvidence",
      "prov:label": "Tinsley & Nadolsky 2025 (SAGE Open Med Case Rep): Case series \u2014 lean soft tissue preserved or gained with structured resistance exercise and high protein during GLP-1 agonist treatment",
      "pe:factId": "B1",
      "pe:evidenceType": "empirical",
      "pe:sourceUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12536186/",
      "pe:sourceName": "Tinsley GM, Nadolsky S. SAGE Open Medical Case Reports 2025. Three patients performed resistance exercise 3\u20135 d/wk + high protein (1.6\u20132.3 g/kg FFM/d) during GLP-1 agonist treatment. DXA showed lean soft tissue preserved or net-gained in 2 of 3 cases; Case 1 lost only 8.7% of weight as lean mass vs. 26\u201340% expected without exercise."
    },
    "pe:evidence-B2": {
      "prov:type": "pe:EmpiricalEvidence",
      "prov:label": "Codella et al. 2025 (Frontiers Clin Diabetes Healthcare): Resistance training attenuates lean body mass loss on GLP-1 drugs",
      "pe:factId": "B2",
      "pe:evidenceType": "empirical",
      "pe:sourceUrl": "https://www.frontiersin.org/journals/clinical-diabetes-and-healthcare/articles/10.3389/fcdhc.2025.1720794/full",
      "pe:sourceName": "Codella R, Senesi P, Luzi L. Frontiers in Clinical Diabetes and Healthcare 2025. Narrative review of GLP-1 agonist pharmacotherapy and exercise interventions."
    },
    "pe:evidence-B3": {
      "prov:type": "pe:EmpiricalEvidence",
      "prov:label": "Apovian et al. 2025 (Mass General Advances in Motion): Exercise + high protein has greatest benefit preserving muscle on GLP-1",
      "pe:factId": "B3",
      "pe:evidenceType": "empirical",
      "pe:sourceUrl": "https://advances.massgeneral.org/endocrinology/article.aspx?id=1601",
      "pe:sourceName": "Apovian C, Yerevanian A, Dushay J. Mass General Advances in Motion 2025. Clinical guidance on preserving lean body mass during GLP-1 receptor agonist therapy."
    },
    "pe:evidence-B4": {
      "prov:type": "pe:EmpiricalEvidence",
      "prov:label": "Daneshgaran et al. 2025 (Aesthetic Surg J Open Forum): Systematic review \u2014 evidence for GLP-1-specific facial fat atrophy is lacking",
      "pe:factId": "B4",
      "pe:evidenceType": "empirical",
      "pe:sourceUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12232544/",
      "pe:sourceName": "Daneshgaran G, Shauly O, Gould DJ. Aesthetic Surgery Journal Open Forum 2025. Systematic review of GLP-1 agonist weight loss and 'Ozempic face' claims; found the term likely represents general rapid weight-loss facial changes."
    },
    "pe:evidence-B5": {
      "prov:type": "pe:EmpiricalEvidence",
      "prov:label": "Haines 2025 (ENDO 2025 / Endocrine Society): Higher protein intake may protect against semaglutide-associated muscle loss",
      "pe:factId": "B5",
      "pe:evidenceType": "empirical",
      "pe:sourceUrl": "https://www.endocrine.org/news-and-advocacy/news-room/endo-annual-meeting/endo-2025-press-releases/haines-press-release",
      "pe:sourceName": "Haines M. ENDO 2025, Endocrine Society. Clinical study (n=40): protein intake associated with reduced lean-mass loss on semaglutide; higher protein protective particularly in older adults and women."
    },
    "pe:evidence-A1": {
      "prov:type": "pe:ComputedEvidence",
      "prov:label": "SC1 verified source count \u2014 lean-mass loss is avoidable",
      "pe:factId": "A1",
      "pe:evidenceType": "computed",
      "pe:method": "count(status in ('verified', 'partial')) over SC1_KEYS",
      "pe:result": "3 of 3 SC1 sources verified (threshold >= 3)"
    },
    "pe:evidence-A2": {
      "prov:type": "pe:ComputedEvidence",
      "prov:label": "SC2 verified source count \u2014 'Ozempic face' not GLP-1-specific",
      "pe:factId": "A2",
      "pe:evidenceType": "computed",
      "pe:method": "count(status in ('verified', 'partial')) over SC2_KEYS",
      "pe:result": "2 of 2 SC2 sources verified (threshold >= 2)"
    },
    "pe:verdict": {
      "prov:type": "pe:Verdict",
      "prov:label": "Verdict: DISPROVED",
      "prov:value": "DISPROVED",
      "pe:doi": "10.5281/zenodo.19489787"
    }
  },
  "activity": {
    "pe:verify-B1": {
      "prov:type": "pe:CitationVerification",
      "prov:label": "Verify B1: Tinsley GM, Nadolsky S. SAGE Open Medical Case Reports 2025. Three patients performed resistance exercise 3\u20135 d/wk + high protein (1.6\u20132.3 g/kg FFM/d) during GLP-1 agonist treatment. DXA showed lean soft tissue preserved or net-gained in 2 of 3 cases; Case 1 lost only 8.7% of weight as lean mass vs. 26\u201340% expected without exercise.",
      "pe:status": "verified",
      "pe:method": "full_quote",
      "pe:fetchMode": "live"
    },
    "pe:verify-B2": {
      "prov:type": "pe:CitationVerification",
      "prov:label": "Verify B2: Codella R, Senesi P, Luzi L. Frontiers in Clinical Diabetes and Healthcare 2025. Narrative review of GLP-1 agonist pharmacotherapy and exercise interventions.",
      "pe:status": "verified",
      "pe:method": "full_quote",
      "pe:fetchMode": "live"
    },
    "pe:verify-B3": {
      "prov:type": "pe:CitationVerification",
      "prov:label": "Verify B3: Apovian C, Yerevanian A, Dushay J. Mass General Advances in Motion 2025. Clinical guidance on preserving lean body mass during GLP-1 receptor agonist therapy.",
      "pe:status": "verified",
      "pe:method": "full_quote",
      "pe:fetchMode": "live"
    },
    "pe:verify-B4": {
      "prov:type": "pe:CitationVerification",
      "prov:label": "Verify B4: Daneshgaran G, Shauly O, Gould DJ. Aesthetic Surgery Journal Open Forum 2025. Systematic review of GLP-1 agonist weight loss and 'Ozempic face' claims; found the term likely represents general rapid weight-loss facial changes.",
      "pe:status": "verified",
      "pe:method": "full_quote",
      "pe:fetchMode": "live"
    },
    "pe:verify-B5": {
      "prov:type": "pe:CitationVerification",
      "prov:label": "Verify B5: Haines M. ENDO 2025, Endocrine Society. Clinical study (n=40): protein intake associated with reduced lean-mass loss on semaglutide; higher protein protective particularly in older adults and women.",
      "pe:status": "verified",
      "pe:method": "full_quote",
      "pe:fetchMode": "live"
    },
    "pe:determine-verdict": {
      "prov:type": "pe:VerdictDetermination",
      "prov:label": "Determine verdict from evidence",
      "prov:endTime": "2026-04-01"
    }
  },
  "agent": {
    "pe:proof-engine": {
      "prov:type": "prov:SoftwareAgent",
      "prov:label": "Proof Engine",
      "schema:version": "1.3.1",
      "schema:url": "https://github.com/yaniv-golan/proof-engine"
    }
  },
  "wasGeneratedBy": {
    "pe:gen-B1": {
      "prov:entity": "pe:evidence-B1",
      "prov:activity": "pe:verify-B1"
    },
    "pe:gen-B2": {
      "prov:entity": "pe:evidence-B2",
      "prov:activity": "pe:verify-B2"
    },
    "pe:gen-B3": {
      "prov:entity": "pe:evidence-B3",
      "prov:activity": "pe:verify-B3"
    },
    "pe:gen-B4": {
      "prov:entity": "pe:evidence-B4",
      "prov:activity": "pe:verify-B4"
    },
    "pe:gen-B5": {
      "prov:entity": "pe:evidence-B5",
      "prov:activity": "pe:verify-B5"
    },
    "pe:gen-verdict": {
      "prov:entity": "pe:verdict",
      "prov:activity": "pe:determine-verdict"
    }
  },
  "wasDerivedFrom": {},
  "wasAttributedTo": {
    "pe:attr-verdict": {
      "prov:entity": "pe:verdict",
      "prov:agent": "pe:proof-engine"
    }
  },
  "used": {
    "pe:used-B1": {
      "prov:activity": "pe:determine-verdict",
      "prov:entity": "pe:evidence-B1"
    },
    "pe:used-B2": {
      "prov:activity": "pe:determine-verdict",
      "prov:entity": "pe:evidence-B2"
    },
    "pe:used-B3": {
      "prov:activity": "pe:determine-verdict",
      "prov:entity": "pe:evidence-B3"
    },
    "pe:used-B4": {
      "prov:activity": "pe:determine-verdict",
      "prov:entity": "pe:evidence-B4"
    },
    "pe:used-B5": {
      "prov:activity": "pe:determine-verdict",
      "prov:entity": "pe:evidence-B5"
    },
    "pe:used-A1": {
      "prov:activity": "pe:determine-verdict",
      "prov:entity": "pe:evidence-A1"
    },
    "pe:used-A2": {
      "prov:activity": "pe:determine-verdict",
      "prov:entity": "pe:evidence-A2"
    }
  }
}